99mTc-sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide

Campbell, Scott; Tzortzakakis, Antonios; Javadi, Mehrbod S.; Karlsson, Mattias; Solnes, Lilja B.; Axelsson, Rimma; Allaf, Mohamad E.; Gorin, Michael A.; Rowe, Steven P.

doi:10.1259/bjr.20170526

Cited by 27 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Improved imaging techniques, such as 99mTc-sestamibi SPECT/CT, also possess the potential to provide patients with additional information as an alternative to biopsy to augment management decisions, but these are not yet widely employed or available. 20,21…”

Section: Discussionmentioning

confidence: 99%

Renal Mass Biopsy is Associated with Reduction in Surgery for Early-Stage Kidney Cancer

Patel

Nichols

et al. 2020

Urology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Renal Mass Biopsy is Associated with Reduction in Surgery for Early-Stage Kidney Cancer

Patel

Nichols

et al. 2020

Urology

View full text Add to dashboard Cite

“…Patients who required further characterization of their renal mass priorto proceeding with treatment, based on the discretion of the treating urologist, were selected to undergo further imaging with MIBI SPECT-CT as part of standard of care. 20 All patients provided consent to undergo the imaging investigations, renal mass biopsy, or surgical excision; and all care was funded by the Ontario Health Insurance Plan (OHIP). Data was subsequently collected and analyzed in a retrospective manner.…”

Section: Methodsmentioning

confidence: 99%

“…16 There have been very few studies investigating the role of 99m Tc-sestamibi single photon emission computed tomography-computed tomography (MIBI SPECT-CT) in the assessment of renal masses. [17][18][19][20] The purpose of this study was to evaluate this role further in the Canadian health care system, and also define the value of MIBI SPECT-CT in the risk stratification of renal masses.…”

Section: Cuaj -Original Researchmentioning

confidence: 99%

The value of 99mTc-sestamibi single-photon emission computed tomography-computed tomography in the evaluation and risk stratification of renal masses

Sistani

Bjazevic

Kassam

et al. 2020

CUAJ

View full text Add to dashboard Cite

Introduction: Differentiation of renal cell carcinoma (RCC) from oncocytoma is a common diagnostic dilemma. A few studies have shown that 99mTc-sestamibi (MIBI) imaging has the potential to characterize indeterminate renal masses. This comparative study evaluated the utility of MIBI single-photon emission computed tomography-computed tomography (SPECT-CT) in the assessment and risk stratification of renal masses. Methods: A total of 29 patients with 31 renal masses who had cross-sectional imaging and MIBI SPECT-CT, were included. Lesions were categorized as either MIBI-positive or -negative on SPECT-CT. Individual lesion density ranged from 22–56 Hounsfield Units (HU) on the non-contrast CT part of SPECT-CT. Quantitative relative MIBI uptake was calculated by measuring tumor to ipsilateral renal parenchymal uptake. The imaging results were correlated with histopathology. Results: All oncocytic lesions, including seven oncocytomas and one hybrid oncocytic chromophobe tumor (100%), were positive on MIBI. One chromophobe RCC showed low-grade MIBI uptake. The remaining RCC subtypes, including 15 clear-cell, four papillary, two mixed clear-cell and papillary, and one chromophobe were MIBI-negative. The quantitative relative tumor uptake showed statistically significant higher uptake in the low-risk/oncocytic lesions compared to RCCs. Conclusions: This study demonstrates that MIBI SPECT-CT is valuable in the characterization of indeterminate renal masses. The combination of MIBI uptake on SPECT and lesion density on non-contrast CT can be used for risk stratification of renal masses. This technique may reduce the need for further imaging (multiphasic CT or magnetic resonance imaging), renal mass biopsy, or surgical resection of low-risk renal masses. Subsequently, more patients could be followed with active surveillance.

show abstract

“…This test is based on normal renal parenchymal uptake of the radiotracer, which allows the differentiation between oncocytoma and RCC. Oncocytoma will demonstrate increased radiotracer uptake similar to the surrounding parenchyma while RCC will have lower uptake relative to the surrounding parenchyma [ 39 ].…”

Section: Reviewmentioning

confidence: 99%

A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma

Morshid¹,

Duran²,

Choi³

et al. 2021

Cureus

View full text Add to dashboard Cite

The evaluation of renal cell carcinoma (RCC) is routinely performed using the multimodality imaging approach, including ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). Ultrasonography is the most frequently used imaging modality for the initial diagnosis of renal masses. The modality of choice for the characterization of the renal mass is multiphasic CT. Recent advances in CT technology have led to its widespread use as a powerful tool for preoperative planning, reducing the need for catheter angiography for the evaluation of vascular invasion. CT is also the standard imaging modality for staging and follow-up. MRI serves as a problem-solving tool in selected cases of undefined renal lesions. Newer MRI techniques, such as arterial spin labeling and diffusion-weighted imaging, have the potential to characterize renal lesions without contrast media, but these techniques warrant further investigation. PET may be a useful tool for evaluating patients with suspected metastatic disease, but it has modest sensitivity in the diagnosis and staging of RCC. The newer radiotracers may increase the accuracy of PET for RCC diagnosis and staging. In summary, the main imaging modality used for the characterization, staging, and surveillance of RCC is multiphasic CT. Other imaging modalities, such as MRI and PET, are used for selected indications.

show abstract

99mTc-sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide

Cited by 27 publications

References 20 publications

Renal Mass Biopsy is Associated with Reduction in Surgery for Early-Stage Kidney Cancer

Renal Mass Biopsy is Associated with Reduction in Surgery for Early-Stage Kidney Cancer

The value of 99mTc-sestamibi single-photon emission computed tomography-computed tomography in the evaluation and risk stratification of renal masses

A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma

Contact Info

Product

Resources

About